Gland Pharma Limited (GLAND) Earnings Call Transcripts

Gland Pharma Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Gland Pharma Limited reported robust financial results, with revenues of INR 17,428 million, reflecting a 22% year-on-year growth, and an adjusted profit after tax of INR 3,667 million, resulting in a 21% margin. The full year revenue reached INR 64,307 million, up 14.5% YoY, driven by strong performance in the CDMO segment, which constituted 46% of total revenues. Management maintained a positive outlook, targeting a revenue growth of 12-13% for FY '27, supported by new product launches and CDMO contracts.

Reported metrics

Guidance from management

Management expects revenue growth of 12-13% for FY '27, supported by new product launches and CDMO contracts. They indicated that this guidance excludes potential contributions from GLP-1 products.

What management said

Yes. As we said, I think we could launch the major CDMO products and also the 2 large products, [indiscernible] launched in March. So that is the ninth year that product I imagine and also the several CDMO projects that got launched in this quarter. And this is the annual year and these are long-term contracts. So these are -- this will be sustainable in terms of long term.

As we said, they're not actually to any numbers for GLP. Even the guidance we've given is excluding GLP because it all depends on this partner getting approvals in different markets and volumes. So we're not giving any numbers out yet. We're just seeing how many contracts and the events also very difficult to assume right now. So the forecasting of the guidance we give is extruding GLP. So anything which happens and ...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of margins and the impact of geopolitical events on revenue, particularly in the Middle East. There were also inquiries about the capacity utilization at Cenexi and the timeline for GLP-1 product approvals.

Main topics on the call

• Strong Revenue Growth — Gland Pharma achieved Q4 revenues of INR 17,428 million, a 22% increase YoY, driven by new product launches and increased volumes. Management stated, "This has been a very strong quarter and a year for us in terms of rev...
• CDMO Segment Performance — The CDMO segment grew by 28% YoY, contributing 46% of total revenues. Management highlighted that "the CDMO business represented 46% of total revenues supported by healthy growth of 28%."
• Cenexi Contribution — Cenexi reported revenues of EUR 45 million in Q4, marking a 4% increase YoY. Management noted that "Cenexi is now EBITDA positive, operationally stable and poised for growth," indicating a turnaround.
• Future Guidance — Management provided guidance for FY '27, projecting revenue growth of 12-13%, excluding GLP-1 products. They stated, "We remain confident of its continued contribution to both revenue growth and margin expansion over the...

Read the full Gland Pharma Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 Gland Pharma Limited earnings call transcripts on record, spanning January 22, 2021 to August 10, 2026. Based on this history, Gland Pharma Limited reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GLAND

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

21

First call

January 22, 2021

Most recent

August 10, 2026

Reporting cadence

quarterly